1. Home
  2. GENC vs ENGN Comparison

GENC vs ENGN Comparison

Compare GENC & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gencor Industries Inc.

GENC

Gencor Industries Inc.

HOLD

Current Price

$15.24

Market Cap

222.5M

Sector

Industrials

ML Signal

HOLD

Logo enGene Holdings Inc.

ENGN

enGene Holdings Inc.

HOLD

Current Price

$1.79

Market Cap

117.2M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
GENC
ENGN
Founded
N/A
1999
Country
United States
Canada
Employees
N/A
82
Industry
Construction/Ag Equipment/Trucks
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
222.5M
117.2M
IPO Year
1995
N/A

Fundamental Metrics

Financial Performance
Metric
GENC
ENGN
Price
$15.24
$1.79
Analyst Decision
Strong Buy
Buy
Analyst Count
1
6
Target Price
$17.60
$21.08
AVG Volume (30 Days)
28.7K
906.7K
Earning Date
02-06-2026
06-11-2026
Dividend Yield
N/A
N/A
EPS Growth
8.08
N/A
EPS
0.50
N/A
Revenue
$48,943,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$25.51
N/A
P/E Ratio
$30.04
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.22
$1.40
52 Week High
$17.40
$12.25

Technical Indicators

Market Signals
Indicator
GENC
ENGN
Relative Strength Index (RSI) 53.22 38.41
Support Level $14.55 $1.68
Resistance Level $15.62 $1.85
Average True Range (ATR) 0.38 0.08
MACD 0.02 0.12
Stochastic Oscillator 52.50 68.00

Price Performance

Historical Comparison
GENC
ENGN

About GENC Gencor Industries Inc.

Gencor Industries Inc and its subsidiaries are a manufacturer of heavy machinery used in the production of highway construction materials and environmental control equipment. The Company's products are manufactured in the United States and sold through a combination of Company sales representatives and independent dealers and agents. The Company has one reporting segment, equipment for the highway construction industry. The Company's principal core products include asphalt pavers, hot mix asphalt plants, combustion systems, and fluid heat transfer systems. It operates in the United States, Canada, and other foreign countries, with the majority of revenue coming from the United States.

About ENGN enGene Holdings Inc.

enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.

Share on Social Networks: